Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Average Rating of “Moderate Buy” from Brokerages

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) has earned an average rating of “Moderate Buy” from the ten analysts that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation and nine have given a buy recommendation to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $63.4286.

A number of analysts recently weighed in on DNTH shares. Wedbush increased their price objective on shares of Dianthus Therapeutics from $44.00 to $46.00 and gave the stock an “outperform” rating in a report on Thursday, November 6th. Raymond James Financial restated an “outperform” rating and issued a $63.00 price target (up previously from $56.00) on shares of Dianthus Therapeutics in a research note on Tuesday, September 9th. HC Wainwright boosted their price objective on Dianthus Therapeutics from $40.00 to $47.00 and gave the stock a “buy” rating in a research report on Monday, November 10th. Truist Financial initiated coverage on Dianthus Therapeutics in a report on Tuesday, October 14th. They issued a “buy” rating and a $56.00 price objective for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Wednesday, October 8th.

Insider Activity

In other news, EVP Simrat Randhawa sold 109,031 shares of the stock in a transaction that occurred on Friday, November 14th. The shares were sold at an average price of $38.14, for a total value of $4,158,442.34. Following the completion of the transaction, the executive vice president directly owned 4,000 shares in the company, valued at $152,560. This trade represents a 96.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Ryan Savitz sold 20,000 shares of the business’s stock in a transaction that occurred on Thursday, December 4th. The stock was sold at an average price of $45.18, for a total value of $903,600.00. The disclosure for this sale is available in the SEC filing. Insiders sold 216,538 shares of company stock valued at $8,283,175 in the last ninety days. Corporate insiders own 8.15% of the company’s stock.

Institutional Trading of Dianthus Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. RA Capital Management L.P. increased its holdings in shares of Dianthus Therapeutics by 53.6% in the first quarter. RA Capital Management L.P. now owns 2,866,733 shares of the company’s stock valued at $52,003,000 after buying an additional 1,000,333 shares in the last quarter. Walleye Capital LLC raised its position in shares of Dianthus Therapeutics by 29.0% during the first quarter. Walleye Capital LLC now owns 106,931 shares of the company’s stock worth $1,940,000 after purchasing an additional 24,041 shares during the period. Vestal Point Capital LP raised its position in shares of Dianthus Therapeutics by 58.1% during the first quarter. Vestal Point Capital LP now owns 1,700,069 shares of the company’s stock worth $30,839,000 after purchasing an additional 625,069 shares during the period. Nuveen LLC purchased a new stake in shares of Dianthus Therapeutics during the first quarter valued at $1,168,000. Finally, Sio Capital Management LLC boosted its position in shares of Dianthus Therapeutics by 101.8% in the 2nd quarter. Sio Capital Management LLC now owns 236,070 shares of the company’s stock valued at $4,398,000 after purchasing an additional 119,073 shares during the period. Institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Stock Down 4.5%

Shares of DNTH stock opened at $41.63 on Friday. The company has a market cap of $1.79 billion, a P/E ratio of -11.96 and a beta of 1.56. The business has a 50 day moving average of $38.06 and a two-hundred day moving average of $28.65. Dianthus Therapeutics has a 52 week low of $13.36 and a 52 week high of $45.46.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.11). Dianthus Therapeutics had a negative net margin of 4,106.04% and a negative return on equity of 33.02%. The company had revenue of $0.40 million for the quarter, compared to analyst estimates of $0.58 million. Analysts expect that Dianthus Therapeutics will post -2.61 EPS for the current fiscal year.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.